Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart’s Top Stock Pick. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or
Alnylam Pharmaceuticals (ALNY)
Alnylam Pharmaceuticals (ALNY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 23,494,320
  • Shares Outstanding, K 124,526
  • Annual Sales, $ 1,037 M
  • Annual Income, $ -1,131 M
  • 60-Month Beta 0.48
  • Price/Sales 22.21
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade ALNY with:

Options Overview Details

View History
  • Implied Volatility 40.72% ( -0.49%)
  • Historical Volatility 34.93%
  • IV Percentile 14%
  • IV Rank 3.35%
  • IV High 152.13% on 07/25/22
  • IV Low 36.86% on 05/19/23
  • Put/Call Vol Ratio 0.62
  • Today's Volume 201
  • Volume Avg (30-Day) 381
  • Put/Call OI Ratio 1.20
  • Today's Open Interest 20,337
  • Open Int (30-Day) 22,730

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/23
See More
  • Average Estimate -1.70
  • Number of Estimates 9
  • High Estimate -1.45
  • Low Estimate -1.98
  • Prior Year -2.29
  • Growth Rate Est. (year over year) +25.76%

Price Performance

See More
Period Period Low Period High Performance
1-Month
183.00 +5.83%
on 05/25/23
212.47 -8.85%
on 05/05/23
-5.35 (-2.69%)
since 05/02/23
3-Month
179.19 +8.08%
on 03/10/23
212.47 -8.85%
on 05/05/23
-0.77 (-0.40%)
since 03/02/23
52-Week
122.57 +58.01%
on 06/13/22
242.97 -20.29%
on 12/21/22
+68.17 (+54.32%)
since 06/02/22

Most Recent Stories

More News
Alnylam (ALNY) Q1 Earnings Beat, Product Sales Drive Revenues

Alnylam Pharmaceuticals (ALNY) reports better-than-expected first-quarter 2023 results. Givlaari, Oxlumo and the newly approved Amvuttra drive revenues for the company.

REGN : 739.95 (+1.20%)
ALNY : 193.67 (+2.65%)
NVS : 98.91 (+1.85%)
ADMA : 4.05 (+1.00%)
Alnylam Pharmaceuticals (ALNY) Reports Q1 Loss, Tops Revenue Estimates

Alnylam (ALNY) delivered earnings and revenue surprises of 28.93% and 3.82%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

ALNY : 193.67 (+2.65%)
VCEL : 32.93 (+0.83%)
Alnylam: Q1 Earnings Snapshot

Alnylam: Q1 Earnings Snapshot

ALNY : 193.67 (+2.65%)
Alnylam Pharmaceuticals Reports First Quarter 2023 Financial Results and Highlights Recent Period Activity

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the first quarter ended March 31, 2023 and reviewed recent business...

ALNY : 193.67 (+2.65%)
Alnylam to Webcast Presentation at BofA Securities 2023 Health Care Conference

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that management will present a company overview at the BofA Securities 2023 Health Care Conference...

ALNY : 193.67 (+2.65%)
Alnylam Issues 2022 Corporate Responsibility Report

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today published its 2022 Corporate Responsibility Report . This year’s edition reasserts our commitment to advancing...

ALNY : 193.67 (+2.65%)
Alnylam and Regeneron Report Positive Interim Phase 1 Clinical Data on ALN-APP, an Investigational RNAi Therapeutic for Alzheimer’s Disease and Cerebral Amyloid Angiopathy

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) announced today positive interim results from the ongoing single ascending dose part of the Phase 1 study...

ALNY : 193.67 (+2.65%)
REGN : 739.95 (+1.20%)
Why Legend Biotech Stock Is Having Its Best Month Yet

With the biotech market’s focus back on treatments for cancer and other life-threatening diseases, Legend has now tripled off its bottom to a record high.

LEGN : 63.38 (-0.38%)
JNJ : 156.97 (+1.57%)
BMY : 65.66 (+1.52%)
NVS : 98.91 (+1.85%)
BIIB : 300.20 (-0.73%)
ALNY : 193.67 (+2.65%)
MRKR : 1.8400 (+9.52%)
Will Alnylam Pharmaceuticals (ALNY) Report Negative Q1 Earnings? What You Should Know

Alnylam (ALNY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ALNY : 193.67 (+2.65%)
SLDB : 6.29 (-0.16%)
Alnylam to Webcast Conference Call Discussing First Quarter 2023 Financial Results

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the first quarter ending March 31, 2023 on Thursday, May...

ALNY : 193.67 (+2.65%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Alnylam Pharmaceuticals Inc. is a development-stage biopharmaceutical company focused on the development of novel therapeutics based on RNA interference. The company's pipeline of experimental RNAi therapeutics is focused across three strategic therapeutic areas - genetic medicines, cardio-metabolic...

See More

Key Turning Points

3rd Resistance Point 203.70
2nd Resistance Point 199.75
1st Resistance Point 196.71
Last Price 193.67
1st Support Level 189.72
2nd Support Level 185.77
3rd Support Level 182.73

See More

52-Week High 242.97
Fibonacci 61.8% 196.98
Last Price 193.67
Fibonacci 50% 182.77
Fibonacci 38.2% 168.56
52-Week Low 122.57

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar